Lincoln Pharma Peer Comparison

NSE: LINCOLN | BSE: 531633

₹545.60

₹-9.40 (-1.69%)

As on 16-Oct-2026IST

Market cap

₹1,095 Cr

Revenue (TTM)

₹694 Cr

P/E Ratio

11.3

P/B Ratio

1.4

Div. Yield

0.3 %

Edit

	Lincoln Pharma	Shilpa Medicare	Caplin Point Lab	Pfizer	Eris Lifesciences
Market cap (₹ Cr)	1,095	18,336	17,484	17,475	15,832
Revenue (₹ Cr)	694	1,682	2,287	2,570	3,230
Net Profit (₹ Cr)	96.45	273.51	678.07	735.15	666.92
Net Margin (%)	13.09	16.19	28.10	26.88	20.60
RoE (%)	13.09	11.15	19.73	19.16	18.75
Price to Earnings	11.35	61.67	26.28	23.77	24.59
Price-To-Book	1.38	6.83	4.76	3.97	3.93

Income Statement (₹ Cr)

	Lincoln Pharma	Shilpa Medicare	Caplin Point Lab	Pfizer	Eris Lifesciences
Operating Revenue	694.25	1,682.47	2,287.33	2,569.77	3,229.67
Total Income	736.69	1,689.83	2,413.29	2,735.39	3,237.12
Total Expenditure	592.94	1,203.91	1,490.75	1,628.14	2,090.06
EBITDA	101.31	478.55	796.58	941.63	1,139.61
Depreciation	14.91	126.01	78.10	57.58	281.06
EBIT	86.40	352.55	718.48	884.05	858.55
Interest	1.06	52.11	0.88	7.69	190.64
Other Income	42.45	7.37	125.96	165.62	7.45
Exceptional Items	0.00	12.16	0.00	-49.16	-17.24
Profit before Tax	127.79	319.96	843.56	992.82	658.12
Provision for Tax	31.34	46.45	165.49	257.67	-8.80
Profit after Tax	96.45	273.51	678.07	735.15	666.92

	Lincoln Pharma	Shilpa Medicare	Caplin Point Lab	Pfizer	Eris Lifesciences
Shareholder's Funds	757.63	2,591.20	3,586.42	4,202.90	3,902.67
Minority Interest	0.00	0.00	-12.71	0.00	-21.81
Non-Current Liabilities	21.73	266.35	28.74	91.50	1,392.75
Current Liabilities	111.05	848.06	385.94	627.48	2,077.10
Total Liabilities	916.12	3,705.61	4,037.51	4,921.88	7,246.72

	Lincoln Pharma	Shilpa Medicare	Caplin Point Lab	Pfizer	Eris Lifesciences
Non-Current Assets	302.96	2,525.44	1,291.22	770.28	5,617.77
Current Assets	583.06	1,109.77	2,585.66	3,803.22	1,539.85
Total Assets	916.12	3,705.61	4,037.51	4,921.88	7,246.72
Total Debt*	4.42	657.97	0.57	2.50	2,309.68
Net Current Assets	472.01	261.71	2,199.72	3,175.74	-537.25
Contingent Liabilities	4.48	160.01	17.53	370.49	51.57

	Lincoln Pharma	Shilpa Medicare	Caplin Point Lab	Pfizer	Eris Lifesciences
Cash From Operating Activities	106.36	342.18	523.24	967.57	537.99
Cash Flow from Investing Activities	-98.41	-325.92	-582.30	-561.67	-369.46
Cash from Financing Activities	0.16	13.62	-46.46	-798.31	-313.53
Net Cash Inflow / Outflow	8.11	29.88	-105.52	-392.41	-145.00

	Lincoln Pharma	Shilpa Medicare	Caplin Point Lab	Pfizer	Eris Lifesciences
ROCE (%)	16.27	11.43	24.97	23.39	14.47
ROE (%)	13.09	11.15	19.73	19.16	18.75
ROA (%)	11.43	7.80	18.69	14.95	9.26
EBIT Margin (%)	12.45	20.95	31.41	34.40	26.58
Net Margin (%)	13.09	16.19	28.10	26.88	20.60
Cash Profit Margin (%)	0.00	0.00	0.00	0.00	0.00

	Lincoln Pharma	Shilpa Medicare	Caplin Point Lab	Pfizer	Eris Lifesciences
Revenue Growth (%)	10.19	27.91	15.01	10.69	9.59
EBIT Growth (%)	-3.37	58.32	18.45	24.14	16.84
Net Profit Growth (%)	11.70	149.56	19.61	-9.09	62.68
EPS Growth (%)	11.70	-3.57	17.73	14.40	67.41
Book Value Growth (%)	12.80	9.67	26.75	-0.34	36.71

	Lincoln Pharma	Shilpa Medicare	Caplin Point Lab	Pfizer	Eris Lifesciences
Price / Earnings	11.35	65.42	26.28	22.65	23.97
Price / Book Value	1.38	6.83	4.76	3.97	3.93
Dividend Yield (%)	0.33	0.06	0.35	1.96	0.00
EV/EBITDA	8.47	39.60	20.69	15.26	15.86
Market Cap (₹ Cr)	1,130.35	6,819.66	11,439.22	21,592.90	17,980.08

	Lincoln Pharma	Shilpa Medicare	Caplin Point Lab	Pfizer	Eris Lifesciences
Debt to Equity	0.00	0.07	0.00	0.00	0.24
Short term debt to equity ratio	0.01	0.16	0.00	0.00	0.12
Current Ratio	5.25	1.31	6.70	6.06	0.74
Quick Ratio	4.53	0.88	5.59	5.31	0.53
Interest Coverage	121.33	7.14	959.59	130.11	4.45

	Lincoln Pharma	Shilpa Medicare	Caplin Point Lab	Pfizer	Eris Lifesciences
Debtors to sales (%)	23.26	30.84	36.10	7.07	21.07
Asset Turnover	0.82	0.48	0.63	0.52	0.45
Receivable days	85.34	113.81	121.68	26.06	63.88
Inventory Days	41.33	84.76	63.83	65.95	43.27
Payable days	146.25	101.94	108.28	81.01	151.85
Cash Conversion Cycle	-19.58	96.62	77.23	11.00	-44.70

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.